Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Inv. presentation
PROGENICS PHARMACEUTICALS INC (PGNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/08/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/12/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
07/02/2020 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
06/23/2020 4 Das Asha (Chief Medical Officer) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 125,000 options to buy @ $4.56, valued at $570k
Disposed/sold 82,214 options to buy @ $4.77, valued at $392.2k
06/23/2020 4 Osorio Benedict (COO) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 21,202 shares @ $0
Disposed/sold 100,000 options to buy @ $6.62, valued at $662k
Disposed/sold 90,750 options to buy @ $4.52, valued at $410.2k
Disposed/sold 82,214 options to buy @ $4.77, valued at $392.2k
06/23/2020 4 Tenbarge Bryce (SVP, Commercial) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 75,000 options to buy @ $6.77, valued at $507.8k
Disposed/sold 66,000 options to buy @ $11.32, valued at $747.1k
Disposed/sold 75,900 options to buy @ $6.62, valued at $502.5k
Disposed/sold 90,750 options to buy @ $4.52, valued at $410.2k
Disposed/sold 82,214 options to buy @ $4.77, valued at $392.2k
06/23/2020 4 Wong Vivien (EVP, Development) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 4,121 shares @ $0
Disposed/sold 6,000 options to buy @ $5.35, valued at $32.1k
Disposed/sold 25,000 options to buy @ $4.83, valued at $120.8k
Disposed/sold 60,000 options to buy @ $7.4, valued at $444k
Disposed/sold 40,000 options to buy @ $9.81, valued at $392.4k
Disposed/sold 48,000 options to buy @ $5.03, valued at $241.4k
Disposed/sold 52,800 options to buy @ $4.7, valued at $248.2k
Disposed/sold 75,000 options to buy @ $4.7, valued at $352.5k
Disposed/sold 66,000 options to buy @ $6.65, valued at $438.9k
Disposed/sold 82,500 options to buy @ $4.52, valued at $372.9k
Disposed/sold 82,500 options to buy @ $11.32, valued at $933.9k
06/23/2020 4 Mims David W. (Interim CEO and Interim CFO) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 40,000 options to buy @ $5.01, valued at $200.4k
Disposed/sold 16,393 options to buy @ $5.01, valued at $82.1k
06/23/2020 4 Ber Gerard (Director) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 50,000 shares @ $0
Disposed/sold 40,000 options to buy @ $5.01, valued at $200.4k
Disposed/sold 16,393 options to buy @ $5.01, valued at $82.1k
06/23/2020 4 Campbell Bradley L (Director) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 12,000 shares @ $0
Disposed/sold 28,000 options to buy @ $4.89, valued at $136.9k
Disposed/sold 20,000 options to buy @ $6.95, valued at $139k
Disposed/sold 25,000 options to buy @ $8.99, valued at $224.8k
Disposed/sold 25,000 options to buy @ $5.74, valued at $143.5k
06/23/2020 4 Ende Eric J (Director) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 40,000 options to buy @ $5.01, valued at $200.4k
Disposed/sold 16,393 options to buy @ $5.01, valued at $82.1k
06/23/2020 4 Ferrante Karen Jean (Director) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 40,000 options to buy @ $4.5, valued at $180k
Disposed/sold 20,000 options to buy @ $4.47, valued at $89.4k
Disposed/sold 20,000 options to buy @ $6.72, valued at $134.4k
Disposed/sold 20,000 options to buy @ $4.89, valued at $97.8k
Disposed/sold 20,000 options to buy @ $6.95, valued at $139k
Disposed/sold 25,000 options to buy @ $8.99, valued at $224.8k
Disposed/sold 25,000 options to buy @ $5.74, valued at $143.5k
06/23/2020 4 MacDougall Ann L. (Director) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 40,000 options to buy @ $5.01, valued at $200.4k
Disposed/sold 36,065 options to buy @ $5.01, valued at $180.7k
06/23/2020 4 Maeusli Heinz Christoph (Director) has filed a Form 4 on PROGENICS PHARMACEUTICALS INC
Txns: Disposed/sold 40,000 options to buy @ $5.01, valued at $200.4k
Disposed/sold 16,393 options to buy @ $5.01, valued at $82.1k
06/23/2020 SC 13D/A Lantheus Holdings, Inc. reports a 100% stake in Progenics Pharmaceuticals, Inc.
06/22/2020 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
06/22/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/22/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/22/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/22/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/22/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/22/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/22/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/22/2020 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/22/2020 8-K Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 19, 2020 Progenics Pharmaceuticals, Inc. Delaware 000-23143 13-3379479 One World Trade Center, 47th Floor, New York, New York 10007 Registrant's telephone number, including area code: 975-2500 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchang...",
"Fourth Amended and Restated Certificate of Incorporation of Progenics Pharmaceuticals, Inc., effective June 19, 2020",
"Amended and Restated Bylaws of Progenics, effective June 19, 2020",
"Lantheus Completes Merger with Progenics"
06/17/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 16, 2020 Progenics Pharmaceuticals, Inc. Delaware 000-23143 13-3379479 One World Trade Center, 47th Floor, New York, New York 10007 Registrant's telephone number, including area code: 975-2500 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchang..."
06/16/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 16, 2020 Progenics Pharmaceuticals, Inc. Delaware 000-23143 13-3379479 One World Trade Center, 47th Floor, New York, New York 10007 Registrant's telephone number, including area code: 975-2500 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchang...",
"Progenics Stockholders Approve Merger with Lantheus , June 16, 2020 - Progenics Pharmaceuticals, Inc. , an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special meeting of its stockholders held earlier today, Progenics' stockholders voted to approve its proposed merger with Lantheus Holdings, Inc. , a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, by adopting the previously announced Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 , by and among Progenics, Lantheus and Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus , pursuant to which Merger Sub will be merged with and into Progenics , with P..."
06/16/2020 GN Progenics Stockholders Approve Merger with Lantheus
06/11/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/08/2020 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : Progenics Pharmaceuticals, Inc. Delaware 000-23143 13-3379479 One World Trade Center, 47th Floor, New York, New York 10007 Registrant's telephone number, including area code: 975-2500 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#9744..."
06/04/2020 SC 13G/A EAGLE ASSET MANAGEMENT INC reports a 0% stake in Progenics Pharmaceuticals, Inc.
05/28/2020 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
05/18/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "###"
05/14/2020 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy